Renee Maria Saliby

Feb 5, 2024 | bpno.dk | Renee Maria Saliby

Opret en profil og få adgang til BestPractice Nordic platformen Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel, kan du:Få adgang til kliniske nyheder med relevans for dit specialeLæse artikler online og BestPractice Nordic magasinetmed nyt fra dit speciale tilsendt gratisSe MEDtalks med førende specialisterHøre MEDcasts med specialister diskutere patientcases,diagnosticerings- og behandlings­dilemmaerOg meget mere.

Jan 29, 2024 | europeanurology.com | Kosuke Takemura |Matthew Ernst |J. Connor Wells |Audreylie Lemelin |Renee Maria Saliby |Talal El Zarif | +10 more

AbstractPatients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population from clinical trials. We analyzed data for patients with or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total of 389/4799 patients (8.1%) had BrM on initiation of systemic therapy.

Dec 4, 2023 | nature.com | Shahabbedin Sotudian |Xintao Qiu |Renee Maria Saliby |Rong Li |Cindy H Chau |James A. DeCaprio | +14 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02605-z, published online 21 October 2023. This article was originally published under a standard Springer Nature license (© The Author(s), under exclusive licence to Springer Nature America, Inc.); it is now available as an open-access paper under a Creative Commons Attribution 4.0 International license, © The Author(s). The error has been corrected in the HTML and PDF versions of the article.

Oct 21, 2023 | nature.com | Xintao Qiu |Renee Maria Saliby |Rong Li |Cindy H Chau |James A. DeCaprio |William D Figg | +14 more

AbstractAlthough circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and their dynamic changes during the course of disease. To address these limitations, we developed a method for comprehensive epigenomic profiling of cancer from 1 ml of patient plasma.